BioAge Labs Prepares for Significant Investor Engagements
BioAge Labs (NASDAQ: BIOA), a progressive biopharmaceutical company renowned for its innovative approaches to tackling metabolic diseases by targeting the intricacies of human aging, has declared exciting incoming participation in several notable investor conferences.
Details of Upcoming Conferences
During the Piper Sandler 36th Annual Healthcare Conference taking place in December, Kristen Fortney, PhD, who is both the CEO and co-founder of BioAge, will deliver a pivotal presentation. This event, noteworthy for its gathering of healthcare leaders, provides an invaluable platform for BioAge to showcase its innovative pipeline. Scheduled for December 3, 2024, from 1:30 PM to 1:55 PM EST, it marks a significant moment for the company and investors alike. Attendees can tune into the live presentation through registration.
One-on-One Meetings at Key Conferences
In addition to the panel discussions, BioAge is thrilled to partake in one-on-one meetings, which allows for detailed interactions and deeper insights into the company’s groundbreaking research and development initiatives. These consultations serve as a vital opportunity for potential investors to engage directly with BioAge leadership.
Participation in the Citi Global Healthcare Conference
Simultaneously, at the Citi 2024 Global Healthcare Conference scheduled for December, Kristen Fortney will again take to the stage to present BioAge's advancements. Her presentation, set for December 4, 2024, from 3:15 PM to 3:55 PM EST, is expected to capture the attention of an audience eager to learn about BioAge's latest developments and future directions. For excited stakeholders, access to the hosts’ live webcast for this event is also made available through registration.
Access to Webcast Replays
For those who cannot attend the live presentations, don't worry—replays will be accessible on the company's dedicated investor relations section of their website. These replays will remain available for 30 days following the conferences, ensuring all interested parties can catch up on the insights shared during the events.
About BioAge Labs, Inc.
BioAge Labs is at the forefront of a critical movement in healthcare, focusing on the aging process itself to develop effective therapeutic candidates for ailments such as obesity. With a compelling candidate, azelaprag, leading the charge, the company’s mission centers on interaction with several metabolic pathways that deteriorate as one ages. The small molecule has displayed promising outcomes in promoting metabolism and preventing muscle atrophy, particularly observed in a Phase 1b clinical trial.
Advancing Obesity Treatments
Recently, BioAge commenced a Phase 2 clinical trial that combines azelaprag with tirzepatide, aimed at older adults battling obesity. This innovative approach indicates potential for enhanced weight loss and improved body composition for patients undergoing treatment with incretin drugs, which have shown efficacy in weight management.
Expanding the Pipeline
In addition to their primary focus on obesity, BioAge is actively exploring orally available small molecule brain-penetrant NLRP3 inhibitors intended for conditions driven by neuroinflammation, opening further avenues for impactful therapies. With an emphasis on metabolic aging, BioAge's preclinical programs leverage groundbreaking insights from the company's proprietary platform rooted in human longevity research.
Contact Information
For further inquiries, BioAge encourages interested parties to reach out via various channels. Chris Patil oversees public relations and can be contacted at the office, while Elena Liapounova handles investor relations—both extending invitations for robust discussions about BioAge’s trajectory. Additionally, partnerships can be explored by contacting the designated team via email.
Frequently Asked Questions
What is the purpose of BioAge Labs attending these conferences?
BioAge Labs aims to showcase its innovative projects and engage potential investors in insightful discussions about its pipeline and clinical trials.
When will the presentations by BioAge Labs occur?
The presentations are slated for December 3 and December 4, 2024, during key healthcare conferences.
How can I access the webcasts of the presentations?
Those interested can register online to access the live webcasts during the scheduled presentation times.
What notable products is BioAge Labs developing?
BioAge Labs is focusing on azelaprag for obesity treatment and exploring NLRP3 inhibitors for neuroinflammatory diseases.
Who can be contacted for more information about BioAge Labs?
Contact Chris Patil for media inquiries, Elena Liapounova for investor relations, or reach out for partnerships via the indicated emails.
